Desktop Health™ Announces Hannover Medical School Has Implanted the First Adult Custom Ear Implant with Drug Release Benefits Manufactured on the 3D-Bioplotter®
- An adult patient recently received the implant, produced on the Desktop Health 3D-Bioplotter® Manufacturer Series
- This project is highlighted in a new video showcasing how the Hannover Medical School’s ENT clinic uses the premium bioprinter at Team.DM.com/MHH
- The 3D-Bioplotter has now been used for two separate in-patient applications in Germany and the United States, as bioprinting applications advance into a new phase of in-patient applications
BOSTON--(BUSINESS WIRE)-- Desktop Health — the trusted production-grade medical 3D printing brand of Desktop Metal, Inc. (NYSE: DM) — today announced that the ENT clinic at Hannover Medical School (MHH) in Germany has used its 3D-Bioplotter Manufacturer Series to produce a customized ear implant with drug release benefits for implantation in an adult patient.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231031818640/en/
The ENT clinic at Hannover Medical School (MHH) in Germany has used its Desktop Health 3D-Bioplotter to produce a customized ear implant with drug release benefits for implantation in an adult patient. A growing number of parts bioprinted on the 3D-Bioplotter are being used in patients. (Photo: Business Wire)
The ENT clinic at MHH is the first in the world to use the Desktop Health 3D-Bioplotter to customize an ear implant for a patient's individual anatomy, print it with integrated pharmaceutical ingredients, and implant it.
“We have thus opened the door to a new type of pioneering patient care," said ENT clinic director Prof. Prof. h.c. Thomas Lenarz, MD.
“Our entire team celebrates this important accomplishment by the Hannover Medical School ENT clinic, which has been years in the making,” said Ric Fulop, Founder and CEO of Desktop Metal. MHH purchased its 3D-Bioplotter in 2020 to develop this and other applications.
Fulop noted that bioprinting is entering a new phase. “The benefits of 3D bioprinting are just beginning to move into actual patients, and we celebrate this important shift in medicine that MHH and other medical innovators are driving forward,” Fulop said. “In recent months, we’ve seen the first products developed over many years on the 3D-Bioplotter moving into commercial and patient applications. We celebrate these important milestones, and what they mean for personalized patient care.”
Earlier this month, Chicago-based Dimension Inx announced that its CMFlex™ synthetic bone graft product has been surgically implanted in two cases. This product — the first 3D printed regenerative bone graft product cleared by the FDA — was developed and is manufactured on the 3D-Bioplotter Manufacturer Series.
Details about the Ear Implant
The MHH patient who received the implant suffered from recurrent narrowing of the auditory canal, which had been treated surgically several times without showing the desired success. The new implant serves a stent function, but also delivers ingredients designed to accelerate healing.
“The first follow-up has already been very promising,” said PD Dr. Verena Scheper, whose team from the Otolaryngology Clinic’s Inner Ear Pharmacology Department designed the implant and manufactured it using the 3D-Bioplotter Manufacturing Series.
The MHH ENT Clinic is internationally renowned for the world's largest cochlear implant program for the care of hearing-impaired patients. To date, the clinic has provided more than 11,111 affected persons with a cochlear implant. Other areas of focus include the provision of hearing aids and their further development, the early detection of childhood hearing loss, and the diagnosis and treatment of sensorineural hearing loss, including tinnitus. The treatment of patients is based on the close cooperation between the ENT clinic, the German Hearing Center Hannover (DHZ), acousticians, product manufacturers and scientists up to the development of new medical products.
The Desktop Health 3D-Bioplotter is a robust, premium bioprinter renowned for its high accuracy and repeatability. It’s also the world’s most cited and researched bioprinter in peer-reviewed scientific and medical journals, with more than 2,490 citations and more than 640 research papers directly produced with the system. To learn more, visit TeamDM.com/biopapers.
About Desktop Metal
Desktop Metal (NYSE:DM) is driving Additive Manufacturing 2.0, a new era of on-demand, digital mass production of industrial, medical, and consumer products. Our innovative 3D printers, materials, and software deliver the speed, cost, and part quality required for this transformation. We’re the original inventors and world leaders of the 3D printing methods we believe will empower this shift, binder jetting and digital light processing. Today, our systems print metal, polymer, sand and other ceramics, as well as foam and recycled wood. Manufacturers use our technology worldwide to save time and money, reduce waste, increase flexibility, and produce designs that solve the world’s toughest problems and enable once-impossible innovations. Learn more about Desktop Metal and our #TeamDM brands at www.desktopmetal.com.
This press release contains certain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to the risks and uncertainties set forth in Desktop Metal, Inc.'s filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Desktop Metal, Inc. assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
Media and Investor Relations:
Source: Desktop Health
Released October 31, 2023